175 results about "Cell aggregation" patented technology

The invention discloses an intelligent traditional Chinese medicine quality detection method and system based on deep learning, and relates to the technical field of medicine health, a high-resolution industrial camera and a multispectral imager are used for collecting multi-angle RGB images and spectral images of different wavebands, and an oil cell aggregation area is identified based on the images. And multi-dimensional detection is carried out from the physical structure and microcellular level, so that the quality detection accuracy of the traditional Chinese medicine decoction pieces is guaranteed in multiple aspects. And deeply analyzing the distribution condition of the oil cells according to the identified oil cell aggregation region, and generating judgment information containing a distribution result and an acid range. The judgment information can accurately reflect the abnormal conditions of the to-be-detected traditional Chinese medicine decoction pieces distributed for the corresponding production places under the current batch, a more comprehensive and detailed basis is provided for traditional Chinese medicine quality evaluation, and through the analysis, the quality difference of the traditional Chinese medicine decoction pieces in different production places can be effectively distinguished, and a deterioration risk signal is generated according to a distribution result.

The present invention relates to a microfluidic device (1) for forming a cell aggregate comprising at least one first cell (C1) and one second cell (C2), and for individually processing selected cells of the cell aggregate: - Microfluidic channel (10); - At least one main inlet (11) for fluids containing a first cell, a second cell, and a third cell, respectively, located in the first portion (101) of the microfluidic channel; - An outlet (12) located in the second portion (102) of the microfluidic channel for controlling the flow rate of fluid within the microfluidic channel; - A first auxiliary inlet (131) for at least one first auxiliary fluid, located in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - At least one cell trapping section (14) positioned between the first and second parts within the microfluidic channel; - At least one first valve to control the flow rate of the first auxiliary fluid, causing the fluid containing the first cells and the second cells to flow at a predetermined height within the microfluidic channel, thereby guiding the first cells and the second cells to the first and second capture units, respectively. Equipped with, The microfluidic device relates to a microfluidic device in which each cell capture section (14) comprises at least one first capture section (141) and one second capture section (142), each first and second capture section being sized to accommodate a first or second cell, the first and second capture sections being adjacent to each other in a direction perpendicular to the bottom (100) of the microfluidic channel, and forming a cell aggregate containing the captured first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel.

Disclosed is a method for producing T cells, the method comprising: (1) culturing three-dimensional cell aggregate(s) comprising cells that can differentiate into T cells, and stromal cells that express Notch ligand(s) derived from pluripotent stem cells. Also disclosed are T cells obtained by the method, and a medicine comprising the T cells.

The invention belongs to the technical field of biology, and particularly relates to an endogenous cell aggregate source exosome and application thereof.The exosome is obtained by culturing mesenchymal stem cells in a 3D cell culture system added with a cell culture medium and IGF-1 to obtain mesenchymal stem cell aggregates and secreting the mesenchymal stem cell aggregates in a culture medium; the cell culture medium is prepared from the following components in parts by weight: 1 to 3 parts of hE-cad-Fc and 1 to 3 parts of hN-cad-Fc. The preparation method of the mesenchymal stem cell source exosome pretreated by combining the cadherin with the IGF-1 has extremely high exosome production efficiency, and the prepared mesenchymal stem cell source exosome pretreated by combining the cadherin with the IGF-1 is complete in structure, uniform in particle size distribution, high in production efficiency and high in effective functional component content.

The invention relates to the technical field of biology, in particular to a matrix-enabled mesenchymal stem cell aggregate and application, and the matrix-enabled mesenchymal stem cell aggregate is obtained by subculturing matrix-enabled mesenchymal stem cells in a 3D cell culture system. The matrix-enabled mesenchymal stem cells are obtained by subculture of mesenchymal stem cells in a cell culture matrix, and the cell culture matrix is prepared from 1-3 parts of hE-cad-Fc and 1-3 parts of hN-cad-Fc. Endogenous epithelium cadherin and nerve cadherin are highly expressed in cell aggregation cells, so that transcription factors are promoted to enter nuclei, the expression levels of anti-inflammatory immune regulation related factors and matrix degradation and cell migration related factors are up-regulated, and activated macrophages are promoted to be polarized to M2 type macrophages; the effects of anti-inflammation, immune regulation, tissue damage repair and the like of intravenous implantation of the matrix-enabled mesenchymal stem cell aggregate for treating diseases such as hepatic fibrosis, diabetes mellitus, nerve injury and the like are remarkably improved.

In one embodiment, cells 12 are suspended inside a hollow capsule 11 including a semipermeable membrane, and the hollow capsule 11 is incubated in a culture medium to allow the cells 12 to aggregate inside the hollow capsule 11. The cells 12 are a mixture of dissociated target cells 14 and auxiliary cells 15 for assisting the aggregation of the target cells 14. The target cells 14 more easily aggregate in the presence of the auxiliary cells 15 than in the absence of the auxiliary cells 15. In another embodiment, dissociated cells 12 are suspended inside a hollow capsule 11 including a semipermeable membrane, and the hollow capsule 11 is incubated in a culture medium to allow the cells to aggregate inside the hollow capsule 11. The cells 12 include at least stromal cells. Thus, an aggregate 21 of the cells 12 is produced.

The present disclosure relates to methods of determining percentage viability of a cell composition comprising cell aggregates. Such methods may include providing a first aliquot of cells and a second aliquot of cells, wherein the first aliquot of cells and the second aliquot of cells have about the same concentration of cells, measuring a total number of live cells in the first aliquot of cells; measuring a total number of cells in the second aliquot of cells, and determining the percentage viability of the cell composition as a ratio between the total number of live cells in the first aliquot of cells and the total number cells in the second aliquot of cells.

The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2):(1) a first step of suspension-culturing pluripotent stem cells to form a cell aggregate in the presence of a Wnt signal transduction pathway inhibiting substance,(2) a second step of suspension-culturing the aggregate obtained in the first step in the presence of a BMP signal transduction pathway activating substance and a Sonic hedgehog signal transduction pathway activating substance, thereby obtaining a cell mass comprising pituitary tissue.

This invention provides a method for propagating pluripotent stem cells (PSCs) by suspension culture in a bioreactor. [Solution] The method comprises the following steps: (i) adding a ROCK inhibitor (ROCKi) to pluripotent stem cells cultured in suspension in a bioreactor; (ii) adding a cell dissociation agent, thereby dissociating aggregates of pluripotent stem cells; (iii) diluting the cell dissociation agent added in step (ii) by adding a sufficient excess volume of culture medium to reduce the concentration of the cell dissociation agent to a concentration at which cell aggregates can be re-formed; and (iv) culturing the mixture obtained in step (iii) under appropriate conditions that allow for the proliferation of PSCs.

In a bioprinting system and method, a bioprinter may include one or more reservoirs, a printhead, and a print surface on which the bioprinting is dispensed. An optical system may collect imaging data of a plurality of cells within a cross-linkable material during and / or after passage of the plurality of cells through the bioprinting system. A computing system may generate, via a machine learning algorithm executing on the image data, a plurality of segmented regions in the image data, wherein each segmented region in the plurality of segmented region defines a boundary around a different set of cell aggregates in the plurality of cells, identify a first segmented region in the plurality of segmented regions that defines a boundary around at least a visible portion of a first cell aggregate, wherein the first cell aggregate includes an occluded portion, determine, based on an estimated shape of the first cell aggregate, an extrapolated boundary around at least some of the visible portion of the first cell aggregate and at least some of the occluded portion of the first cell aggregate, compute a quantity of cells within the first cell aggregate based on an area surrounded by the extrapolated boundary, and determine one or more parameters associated with the plurality of cells, the material flow, or the bioprinting system based on the quantity of cells.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The present invention relates to novel cell culture and transfection methods using a wildtype Caf1 ("Caf1-WT") polymer or a variant thereof. Use of a Caf1-WT polymer or a variant thereof to increase cell viability, cell proliferation, cell migration and / or cell clustering; promote the formation of a 3D cell structure; and / or promote suspension cell culture of cells that are normally adherent are also provided herein.

To provide a method for evaluating the quality of neuroretina for transplantation and neuroretina sheets for transplantation selected by said method. [Solution] The present invention provides a method for evaluating the quality of neuroretina for transplantation, comprising: extracting a part or all of a cell aggregate containing a neuroretina having an epithelial structure derived from pluripotent stem cells as a quality evaluation sample; detecting the expression of neuroretinal cell-related genes and non-neuroretinal cell-related genes in the quality evaluation sample; and determining, if the expression of neuroretinal cell-related genes is observed and the expression of non-neuroretinal cell-related genes is not observed, that (1) a neuroretina (neuroretina for transplantation) from the same cell aggregate as the cell aggregate containing a part of the quality evaluation sample, (2) a neuroretina (neuroretina for transplantation) from the same lot as the cell aggregate containing a part of the quality evaluation sample, or (3) a neuroretina (neuroretina for transplantation) from the same lot as the cell aggregate of the entire quality evaluation sample, wherein the non-neuroretinal cell-related genes include one or more genes selected from the group consisting of brain and spinal cord tissue marker genes and eyeball-related tissue marker genes.

The invention discloses a magnetic suspension three-dimensional cell culture method which comprises the following steps: performing pancreatin digestion, centrifugation and resuspension on cells, inoculating the cells into a pore plate, adding a magnetic nanoparticle solution, performing co-incubation, performing pancreatin digestion, stopping digestion, centrifuging to remove residual magnetic nanoparticles in a culture medium, and adding the culture medium for resuspension; placing a magnetic plate above the pore plate, and carrying out three-dimensional culture in an incubator; a magnet is loaded on the magnetic plate, and one side loaded with the magnet is attached to the pore plate, so that the magnet is always located above the culture medium. According to the invention, the three-dimensional magnetic suspension culture of cells is realized by preparing ferroferric oxide magnetic nanoparticles Fe3O4 (at) DA-PEG (at) PLL for enhancing cell adhesion and designing a three-dimensional culture device for large-scale magnetic suspension cell culture, and the homogenized cell aggregate with a three-dimensional structure is constructed.

The invention discloses an embryo teratogenic substance screening prediction model based on human induced pluripotent stem cells and a construction method thereof, the embryo teratogenic substance screening prediction model is cells and / or cell aggregates, the cells are myocardial cells differentiated from the human induced pluripotent stem cells, and the cell aggregates are embryoid bodies. The embryo teratogenic substance screening prediction model uses human induced pluripotent stem cells to more accurately simulate the environment of human early embryonic development, avoids species difference of animal models, provides a relatively rapid and accurate screening platform, is suitable for high-throughput drug screening, and has good application prospects. Compared with the prior art, the kit has higher sensitivity and specificity, is helpful for eliminating compounds with potential reproductive toxicity in the early stage of drug development, and reduces the risk of later clinical test failure.

The invention relates to a device (1; 1 ') for storing and / or transporting cells, in particular cell aggregates; 10; 15), wherein the device comprises a base (5; 11) and a top (6; 12), wherein the top (6; 12) is located on the base (5; 11), wherein the base (5; 11) is formed from a substrate comprising at least one groove (7) for collecting a fluid, wherein the base (5; 11) and the top (6; 12) is less than the width (9) of the at least one groove (7), and wherein the width (9) of the at least one groove (7) is the smallest line segment between two opposite points passing through the center of the base region of the at least one groove (7).

In a bio-printing system and method, a bio-printer may include one or more reservoirs, a printhead, and a printing surface onto which bio-prints are dispensed. An optical system may collect imaging data of a plurality of cells within a crosslinkable material before, during, and / or after the plurality of cells pass through the bioprinting system. A computing system may process the imaging data to determine a number, distribution, concentration, and / or morphology of the plurality of cells. The machine learning system compares characteristics of the plurality of cells before, during and / or after the plurality of cells pass through the bioprinting system to a user established cellular morphology corresponding to physical characteristics of cells and / or cell aggregates within a predetermined tolerance. Additionally or alternatively, the machine learning system compares characteristics of a plurality of cells at one stage in the bioprinting system to characteristics of a plurality of cells at another stage in the bioprinting system.

A liquid treatment device is provided that shears a biological substance including cell aggregates (e.g., organoids) and filters out fragments of cell aggregates (or other biological substances) of a selected cutoff size. Further, methods of shearing a biological substance and screening out fragments of the biological substance of a selected cutoff value with a liquid treatment device are provided, including without contacting the device with another solid object.

There was a demand for a culture method that would allow for the large-scale culture of cells requiring three-dimensional culture, such as organoids and gastroids, using simple equipment. [Solution] An initial culture step in which target cells and culture medium are placed in a cylindrical culture vessel, and culture is performed using a horizontal rotation culture method in which the culture vessel is rotated with its side facing downwards in the direction of gravity and the length of the cylinder as the central axis, An induction culture step in which the culture medium is replaced with a culture medium containing an organoid inducer and cultured using the horizontal rotation culture method, The three-dimensional culture method for organoids, characterized by having a culture step in which the culture medium is replaced with a culture medium containing polysaccharides but not containing the organoid inducer, and cultured using the horizontal rotation culture method, allows for the large-scale culture of organoids without the cell aggregate adhering to any wall of the culture vessel, even when it grows large.

The invention belongs to the technical field of biomedical engineering and microfluidics, and particularly discloses a circular chamber organ chip for efficient tumor sphere culture, the circular chamber organ chip comprises a runner layer and a bottom layer which are stacked, and the lower surface of the runner layer and the bottom layer are sealed through bonding; a culture solution channel is arranged on the lower surface of the runner layer, snakelike pipelines are symmetrically arranged on the culture solution channel, and a first liquid injection channel and a second liquid injection channel are arranged at the two ends of the culture solution channel respectively; a cell culture chamber communicated with the culture solution channel is arranged on the lower surface of the runner layer; according to the cell culture chamber disclosed by the invention, by adopting a circular tissue chamber structure, the aggregation behavior of cells in a three-dimensional matrix can be obviously optimized, the cell wall attachment tendency and the asymmetric wall attachment probability are obviously reduced, and a plurality of tumor cells can be promoted to quickly and spontaneously form a sphere-like structure in a chip; the probability that the tumor balls are irregular in shape and uneven in growth is reduced, the tumor balls can be conveniently cultured, and a standardized and repeatable three-dimensional tumor model can be established.

The invention provides a real-time monitoring and dynamic analysis method for organoid cell aggregation, which realizes a complete process from image preprocessing, feature extraction to data analysis and visual extraction by automatically monitoring an organoid cell aggregation process and processing a cell aggregation image in real time, and extracts morphological useful information from a bright field image. Quantitative analysis is carried out, the rapid coagulation period, the form stable period and the later coagulation period of the organoid cells are clearly monitored in the forms of charts and data files, and support is provided for selection of the optimal induction period of the organoid.

Tissue analysis systems and co-culture casting systems include at least a multi-well co-culture casting plate and a muscle tissue casting plate. Methods of use include seeding a plurality of neuronal culture compartments of the multi-well co-culture casting plate with live neuronal material, seeding a plurality of muscle culture compartments of the muscle tissue casting plate with live muscle material, culturing, in the multi-well co-culture casting plate, a plurality of co-culture tissues that include a muscle cell culture cultured from the live muscle material and in situ neurospheres matured in the cell aggregation features from the live neuronal material, and causing an innervated portion of the live muscle material in each of the co-culture tissues to contract by stimulating the live neuronal material.

The invention provides a whole-brain organoid based on human induced pluripotent stem cells as well as a construction method and application thereof, and belongs to the technical field of organoid construction. The method comprises the following steps: culturing human induced pluripotent stem cells in a complete culture medium to obtain a cell aggregate; culturing in an embryoid body forming culture medium to obtain a spherical embryoid body; culturing in a nerve induction culture medium tissue to form a nerve epithelium structure; embedding the single embryoid body with the nerve epithelium structure in a Matrigel gel drop, culturing in a nerve expansion culture medium to form a nerve epithelium-like structure, and replacing a mature culture medium for culturing to obtain the whole-brain organ. According to the method, by dynamically and accurately regulating and controlling culture parameters, the control ability of a cell differentiation area is improved, and interference of non-target cell types is reduced, so that the efficiency and consistency of embryoid formation and neural differentiation are directly improved, and finally, the obtained mature organoid has a more complete epithelial structure and cell polarity.

The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods.A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.

The application relates to the technical field of medical image processing, in particular to a blood smear evaluation method, device and system based on medical examination. The method adopts a traversal scanning mode to obtain blood cell images of all regions of a blood smear, and constructs an image set in column units. By screening a red blood cell central region and determining a first blood cell region and a second blood cell region, analysis is jointly performed, so that the cell aggregation degree of each blood cell image can be accurately and effectively quantified. A cell aggregation degree sequence is constructed, and uniformity in the sequence is analyzed, so that the observation difficulty of each image set is obtained, an observable region can be screened, and accurate blood smear quality evaluation is realized. The application effectively quantifies the cell aggregation degree in the image through the image acquisition mode of traversal scanning, divides a correct observable region through the special morphology of the blood smear, and then realizes accurate blood smear quality evaluation.

The present disclosure provides a method of identifying an intracellular cryoprotectant expressed by a cell, the method comprising: (a) using a cell that survives in freezing and thawing, (b) modifying the used cell, (c) freezing and thawing the modified cell, and (d) obtaining a modified cell that survives after step (c), an intracellular cryoprotectant expressed by the cell is thus identified, as well as an intracellular cryoprotectant obtained by or which can be obtained by the method.

The application discloses a dispersion mixed solution system capable of reducing cell aggregation in a domestication process and a preparation method thereof. The system comprises 50x concentrated A liquid (100-250 g / L trypsin+12.5 g / L EDTA) and 100x concentrated B liquid (100 g / L P188+10 g / L DS), and realizes long-term stable storage and rapid preparation in the form of concentrated stock solution. When used, the concentrated stock solution is diluted and mixed in proportion, and through the synergistic effect of mild cell lysis and weakening of cell aggregation force, the cell aggregation in the domestication process is efficiently dispersed, and the cell activity and function are maintained. The preparation method is simple, the storage period is long, the dispersion effect is good, and the cell damage is small, and the application provides an effective technical means for cell domestication.

The invention provides a cell microsphere induced bionic periosteum and a preparation method thereof, and belongs to the technical field of bionic periostems.The preparation method comprises the steps that firstly, a PDA-PCL support is prepared, then cell microspheres obtained through a 3D culture plate are loaded on the support, PDSCs in the cell microspheres are dispersed out of an initial cell aggregate through cell culture, and the PDSCs in the cell microspheres are dispersed out of the initial cell aggregate; rapidly proliferating to form a layer of compact cell functional membrane, and preparing to obtain the cell microsphere induced bionic periosteum; the bionic periosteum can provide high-density stem cells, and can continuously secrete bioactive factors necessary for osteogenic differentiation and angiogenesis, so that the bionic periosteum has excellent osteogenic and angiogenesis promoting functions. According to the method provided by the invention, the bionic periosteum for simulating a natural bone environment is created, and a new bone defect repair strategy is provided: the bionic periosteum generated by expanding the PDSCs in the PDA-PCL stent provides a promising way for promoting bone regeneration treatment.

This invention provides a method for efficiently manufacturing three-dimensional structures using food ink (or cell aggregate ink) containing impurities such as granular or fibrous fragments, and also provides food three-dimensional structures or cell aggregate structures manufactured by these methods. [Solution] Multiple frames prepared for molding can be fixed to each other by inserting fixing rods or the like into common positioning holes provided in the frames. Food ink is dispensed into each filling area within the frames, spread and filled by a spreading means, and the surface is smoothed. Then the upper frames are stacked sequentially. These operations are repeated to form a composite. After the composite is fixed, the frames can be removed to obtain a three-dimensional structure (M). M can be used as is, decorated with a food 3D printer, or heated in a microwave or steamed to make it suitable for eating.

The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods.A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.